Brief: Oxford Biotherapeutics Trategic Collaboration With Bristol Myers Squibb To Discover And Develop Next-Generation T-Cell Engagers For Solid Tumours
09/04/2026 12:16
Bristol-Myers Squibb Co BMY.N: OXFORD BIOTHERAPEUTICS: TRATEGIC COLLABORATION WITH BRISTOL MYERS SQUIBB TO DISCOVER AND DEVELOP NEXT-GENERATION T-CELL ENGAGERS FOR SOLID TUMOURS Source text: ID:nGNX36KDy6 Further company coverage: BMY.N
Recent news on Bristol-Myers Squibb Co
See all newsFactbox: Major deals involving US drugmakers and biotechs over the past decade
Brief: Bristol Myers Squibb Announces Dividend
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Izalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC